Target type: biologicalprocess
The process in which a relatively unspecialized T cell acquires specialized features of a mature CD8-positive, alpha-beta T cell. [ISBN:0781735149]
CD8-positive, alpha-beta T cell differentiation is a complex process that begins in the bone marrow and culminates in the development of mature, cytotoxic T lymphocytes (CTLs) capable of recognizing and eliminating virally infected or cancerous cells. This process involves several stages, each characterized by distinct molecular changes and interactions:
**1. Commitment to the T cell lineage:**
- Hematopoietic stem cells (HSCs) in the bone marrow undergo differentiation into multipotent progenitors (MPPs).
- MPPs commit to the lymphoid lineage, giving rise to common lymphoid progenitors (CLPs).
- CLPs express the transcription factor Notch1, which directs them toward the T cell lineage.
**2. Double-negative (DN) thymocyte development:**
- CLPs migrate to the thymus, where they become DN thymocytes.
- DN thymocytes are characterized by the absence of both CD4 and CD8 coreceptors.
- DN thymocytes progress through four distinct stages (DN1-DN4) defined by the expression of CD44 and CD25.
- **DN1 (CD44+CD25-)**: Initial commitment to the T cell lineage, marked by the expression of CD44, a marker for hematopoietic progenitors.
- **DN2 (CD44+CD25+)**: Proliferation and expression of CD25 (IL-2 receptor alpha chain), indicating responsiveness to IL-2 signaling.
- **DN3 (CD44-CD25+)**: Rearrangement of the TCRbeta locus, leading to the generation of a pre-TCR, which signals for proliferation and survival.
- **DN4 (CD44-CD25-)**: Expression of the pre-TCR and commitment to the CD8 lineage.
**3. Double-positive (DP) thymocyte development:**
- DN4 cells upregulate both CD4 and CD8 coreceptors, becoming DP thymocytes.
- DP thymocytes undergo TCRalpha chain rearrangement, resulting in the expression of a complete TCR complex.
- The TCR interacts with self-peptides presented by MHC molecules expressed on thymic stromal cells.
- This interaction triggers a process called positive selection, where thymocytes with TCRs that can bind weakly to self-MHC are allowed to survive.
- The strength of TCR-MHC interactions influences the fate of DP thymocytes.
**4. Single-positive (SP) thymocyte development:**
- DP thymocytes that pass positive selection undergo negative selection.
- **Negative selection** eliminates thymocytes with TCRs that bind strongly to self-MHC, preventing autoimmunity.
- The outcome of negative selection determines the final fate of the thymocyte:
- **CD8 lineage**: Thymocytes with TCRs that interact primarily with MHC class I are directed to the CD8 lineage, becoming CD8 SP thymocytes.
- **CD4 lineage**: Thymocytes with TCRs that interact primarily with MHC class II are directed to the CD4 lineage, becoming CD4 SP thymocytes.
- SP thymocytes undergo further differentiation, acquiring mature CTL characteristics.
**5. Mature CD8+ T cell differentiation:**
- Mature CD8+ T cells are capable of recognizing and eliminating virally infected or cancerous cells.
- They express a variety of effector molecules, including cytotoxic granules containing perforin and granzyme, which induce target cell apoptosis.
- Mature CD8+ T cells can also express cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and lymphotoxin-alpha (LT-α), which contribute to the elimination of infected or cancerous cells.
- Memory CD8+ T cells are generated during the immune response, providing long-term protection against previously encountered pathogens.
**Key transcription factors involved in CD8 T cell differentiation:**
- **Notch1**: Promotes T cell lineage commitment.
- **GATA-3**: Essential for CD4 lineage commitment.
- **Runx3**: Essential for CD8 lineage commitment.
- **Foxo1**: Regulates TCR signaling and promotes CD8 differentiation.
- **Tcf7**: Promotes the survival and differentiation of CD8+ T cells.
- **Bcl11b**: Suppresses CD4 lineage commitment and promotes CD8 lineage development.
- **ThPOK**: Promotes CD4 lineage commitment and suppresses CD8 lineage development.
**Summary:**
- The process of CD8-positive, alpha-beta T cell differentiation involves a series of developmental stages in the thymus, where thymocytes undergo TCR rearrangement, positive and negative selection, and ultimately differentiate into mature, cytotoxic T lymphocytes (CTLs).
- This differentiation process is driven by a complex interplay of signaling pathways, transcription factors, and cell-cell interactions, ensuring the generation of a diverse and functional T cell repertoire capable of effectively responding to a wide range of pathogens and tumor cells.'
"
Protein | Definition | Taxonomy |
---|---|---|
Proteasome subunit beta type-11 | A proteasome subunit beta type-11 that is encoded in the genome of human. [PRO:DNx, UniProtKB:A5LHX3] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
chlorpromazine | chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | organochlorine compound; phenothiazines; tertiary amine | anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug |
bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
sdz 283-910 | SDZ 283-910: structure in first source | ||
benzyloxycarbonylleucyl-leucyl-leucine aldehyde | benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
benzyloxycarbonyl-phe-ala-fluormethylketone | cathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). | ||
am 404 | anilide | ||
lactacystin | lactam; S-substituted L-cysteine | ||
clasto-lactacystin beta-lactone | clasto-lactacystin beta-lactone: active metabolite of lactacystin; inhibits 20 S proteasome; structure in first source | ||
marizomib | marizomib: a proteasome inhibitor from a marine bacterium Salinospora; structure in first source | beta-lactone; gamma-lactam; organic heterobicyclic compound; organochlorine compound; salinosporamide | antineoplastic agent; proteasome inhibitor |
carfilzomib | epoxide; morpholines; tetrapeptide | antineoplastic agent; proteasome inhibitor | |
tyropeptin a | tyropeptin A: proteasome inhibitors produced by Kitasatospora sp. MK993-dF2; structure in first source | dipeptide | |
belactosin a | belactosin A: isolated from Streptomyces; structure in first source | ||
oprozomib | ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source | ||
ixazomib | ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source | benzamides; boronic acids; dichlorobenzene; glycine derivative | antineoplastic agent; apoptosis inducer; drug metabolite; orphan drug; proteasome inhibitor |